A5023616396- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Urinary and Genital Oncology Studies
- Renal and related cancers
- Radiomics and Machine Learning in Medical Imaging
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Multiple and Secondary Primary Cancers
- Molecular Biology Techniques and Applications
- Economic and Financial Impacts of Cancer
- Sexual Differentiation and Disorders
- Prostate Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Immunotherapy and Immune Responses
- Hormonal and reproductive studies
- Epigenetics and DNA Methylation
- Cancer Treatment and Pharmacology
- Electronic Health Records Systems
- Virus-based gene therapy research
- Lymphoma Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Genetic factors in colorectal cancer
University of Wisconsin–Madison
2017-2025
University of Wisconsin Carbone Cancer Center
2018-2025
Wisconsin Institutes for Discovery
2024
Institute for Medical Research
2024
University of Wisconsin System
2024
University of Ljubljana
2021
Institute of Oncology Ljubljana
2021
Immunomedics (United States)
2019
The Barbara Ann Karmanos Cancer Institute
2019
Good Samaritan Hospital
2014-2019
Testicular cancer is relatively uncommon and accounts for <1% of all male tumors. However, it the most common solid tumor in men between ages 20 34 years, global incidence has been steadily rising over past several decades. Several risk factors testicular have identified, including personal or family history cryptorchidism. germ cell tumors (GCTs) comprise 95% malignant arising testes are categorized into 2 main histologic subtypes: seminoma nonseminoma. Although nonseminoma more clinically...
Abstract Background The delivery of DNA into human cells has been the basis advances in understanding gene function and development genetic therapies. Numerous chemical physical approaches have used to deliver DNA, but their efficacy variable is highly dependent on cell type be transfected. Results Studies were undertaken evaluate compare transfection several reagents that electroporation/nucleofection system using both adherent (primary transformed airway epithelial primary fibroblasts as...
Abstract Purpose: Glutaminase is a key enzyme, which supports elevated dependency of tumors on glutamine-dependent biosynthesis metabolic intermediates. Dual targeting glucose and glutamine metabolism by the mTOR inhibitor everolimus plus oral glutaminase telaglenastat showed preclinical synergistic anticancer effects, translated to encouraging safety efficacy findings in phase I trial 2L+ renal cell carcinoma (RCC). This study evaluated (TelaE) versus placebo (PboE) patients with...
Enfortumab vedotin (EV) is a novel antibody-drug conjugate approved for advanced urothelial cancer (aUC) refractory to prior therapy. In the Urothelial Cancer Network Investigate Therapeutic Experiences (UNITE) study, authors looked at experience with EV in patient subsets of interest which activity had not been well defined clinical trials.UNITE was retrospective study patients aUC treated recently agents. This initial analysis focused on EV. Patient data were abstracted from chart reviews...
652 Background: Enfortumab vedotin (EV) is approved for patients (pts) with advanced urothelial carcinoma (aUC) but outcomes in pts histology variants (HV) have not been well described. We hypothesized that presence of HV would impact EV treatment outcomes. Methods: UNITE a multi-site retrospective study aUC treated targeted agents, including 650 regimens. compared to monotherapy pure UC (pUC) relative any and specific HVs. In scans after > 1 cycle EV, observed response rate (ORR) was...
537 Background: MAv is approved in pts with aUC without progression (PD) on 1L platinum-based therapy (PBT). As the pivotal EV trials had not received after PBT, data outcomes post-MAv are limited. We examined multicenter retrospective UNITE study. hypothesized that would be similar to published data. Methods: Pts who sequential MAv, then monotherapy were included. Investigator-assessed observed response rate (ORR) was assessed for evaluable scans ≥ 1 cycle using χ 2 test and logistic...
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following guideline development process as outlined in Methodology Manual . follow Conflict Interest Policy Clinical Practice other guidance (“Guidance”) provided by is not a or definitive guide to treatment options. It intended voluntary use clinicians should be used conjunction independent professional judgment. Guidance may applicable all patients,...
PURPOSE Nearly all men with prostate cancer treated androgen receptor (AR) signaling inhibitors (ARSIs) develop resistance via diverse mechanisms including constitutive activation of the AR pathway, driven by genomic structural alterations, expression splice variants (AR-Vs), or loss dependence and lineage plasticity termed neuroendocrine cancer. Understanding these de novo acquired ARSI is critical for optimizing therapy. MATERIALS AND METHODS A novel liquid biopsy technology was used to...
Background We previously reported a trial using DNA vaccine encoding prostatic acid phosphatase (MVI-816, pTVG-HP), given over 12 weeks concurrently or sequentially with pembrolizumab, in patients mCRPC. report the final analysis of this following two additional treatment arms which mCRPC continued concurrent until progression. Materials and methods Patients were treated MVI-816 pembrolizumab every 3 (arm 3, n=20) 2 4 4, n=20). The primary objectives safety, 6-month progression-free survival...
Patients with bladder cancer (BC) who are cisplatin ineligible or have unresectable disease limited treatment options. Previously, we showed targeting programmed death-ligand 1 (PD-L1) durvalumab (durva) and radiation therapy (RT) combination was safe in BC. We now report results from a phase II study evaluating the toxicity efficacy of durva RT localized BC.This is single-arm, multi-institutional study; N=26. Enrolled patients had pure mixed urothelial BC (T2-4 N0-2 M0) tumors were unfit...
Purpose We have previously reported that a plasmid DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) had greater clinical activity when given in combination with pembrolizumab to patients metastatic, castration-resistant prostate cancer. The current trial was conducted evaluate vaccination PD-1 blockade, using nivolumab, early, recurrent (M0) Methods Patients M0 cancer were treated pTVG-HP (100 µg administered intradermally) and nivolumab (240 mg intravenous infusion) every 2 weeks...
134 Background: Androgen receptor (AR) signaling is the principal driver of PC at all stages. CC-94676 (BMS-986365) a heterobifunctional, first-in-class, orally bioavailable AR LDD designed to induce rapid, sustained, and highly selective degradation in pts who progressed on standard care therapies. We report initial results from an open-label, multicenter study, NCT04428788, evaluating with progressive mCRPC. Methods: Pts mCRPC androgen deprivation therapy, ≥ 1 second generation hormonal...
BACKGROUND. A common germline variant in HSD3B1(1245A>C) encodes for a hyperactive 3β-hydroxysteroid dehydrogenase 1 (3βHSD1) missense that increases metabolic flux from extragonadal precursor steroids to DHT synthesis prostate cancer. Enabling of by HSD3B1(1245C) predicts more rapid clinical resistance castration and sensitivity androgen inhibition. thus appears define subgroup patients who benefit blocking androgens. However, abiraterone, which is administered block androgens, steroidal...
Background Nivolumab plus ipilimumab (NIVO + IPI) has demonstrated long‐term efficacy and safety in patients with previously untreated, advanced renal cell carcinoma (aRCC). Although most phase 3 clinical trials exclude brain metastases, the ongoing, multicohort 3b/4 CheckMate 920 trial (ClincalTrials.gov identifier NCT02982954) evaluated of NIVO IPI a cohort that included aRCC as reported here. Methods Patients untreated asymptomatic metastases received mg/kg 1 every weeks × 4 followed by...
Preclinical studies suggest that inhibition of single-stranded DNA repair by ataxia telangiectasia and Rad3 (ATR) may enhance the cytotoxicity cisplatin, gemcitabine, other chemotherapeutic agents. Cisplatin with gemcitabine remains standard up-front therapy for treatment in patients metastatic urothelial cancer.
Liquid biopsies in metastatic renal cell carcinoma (mRCC) provide a unique approach to understand the molecular basis of treatment response and resistance. This is particularly important context immunotherapies, which target key immune-tumor interactions. Unlike tissue biopsies, serial real-time profiling mRCC feasible with our noninvasive circulating tumor (CTC) approach.We collected 457 longitudinal liquid from 104 patients enrolled one two studies, either prospective cohort or phase II...
Neutrophil-to-lymphocyte ratios (NLR) and eosinophil counts are associated with improved survival in melanoma patients treated immune checkpoint inhibitors, but no study has investigated neutrophil-to-eosinophil (NER) as a predictive indicator this population. In retrospective evaluating anti-PD-1 advanced melanoma, progression-free (PFS), overall (OS), objective response rates (ORR), risk of high-grade (grade ≥3) immune-related adverse events (irAEs) were compared between groups defined by...
Metastatic castration-resistant prostate cancer (mCRPC) that progresses on androgen receptor pathway inhibitors (ARPIs) may continue to be driven by AR signaling. BMS-986365 is an orally administered ligand-directed degrader targeting the via a first-in-class dual mechanism of degradation and antagonism. CC-94676-PCA-001 (NCT04428788) phase I multicenter study in patients with progressive mCRPC.
Electronic patient‐reported outcome (ePRO) programs may offer advantages for patients with cancer, clinicians, health care systems, payors, and society in general; but developing maintaining an ePRO program will require cancer centers to navigate defining meaningful problems, collecting ePROs, implementing action when those ePROs intervention without over‐burdening monitoring the successes failures of their programs. Physician informaticists from National Comprehensive Cancer Network Health...
667 Background: SG is approved in pts with aUC refractory to platinum-based chemotherapy (PBT) and checkpoint inhibitor therapy (CPI). Data on outcomes subtype/variant histologies (VH) are limited. We examined SG-treated the UNITE study hypothesized that would be similar between pure urothelial histology (pUC) any VH component. Methods: a multi-site retrospective of treated (Tx) targeted agents, such as enfortumab vedotin (EV) SG. Pts who received monotherapy were included this analysis....